[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site

Study’s contact

Call center

1-888-669-6682

Email address

Novartis.email@novartis.com

Condition

Multiple Sclerosis,Multiple Sclerosis, Relapsing MS, Advancing Multiple Sclerosis

Treatment type

Interventional

Investigational product

Siponimod

Phase

Phase 3

Sponsor

Novartis

ClinicalTrials.gov identifier

NCT03623243

Study number

CBAF312AUS02

Understanding clinical trials

Get answers to your questions about clinical trials.

About the study

To assess safety and tolerability of patients converting from approved Relapsing Multiple Sclerosis (RMS) Disease Modifying Therapies (DMTs) to siponimod.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria
Exclusion criteria
  1. lactating) women. 2. Patients with any medically unstable condition as determined by the investigator. 3. History of hypersensitivity to the study drug or to drugs of similar chemical classes. Other protocol-defined inclusion/exclusion criteria may apply.

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site

Featured Trials